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Case presentation
A 45-year-old woman had been dialyzed for 3 years for end-stage renal
disease secondary to polycystic kidney disease. She had received two
transfusions and had developed antibodies reacting with 20% of the local
screening panel. The patient was offered renal transplantation and agreed
to enroll in a randomized study to evaluate the efficacy of a monoclonal
antibody (mAb), directed against an adhesion/co-stimulatory molecule,
CDIIa, in improving graft survival. In this study, the antibody, which had
yielded encouraging results in a recent pilot study, was compared (in an
induction protocol) with anti-thymocyte polyclonal globulins. The proto-
col called for the monoclonal antibody to be administered at 20 mg/day for
10 days, along with 1 mg/kg of steroids (tapered every week, until complete
withdrawal at day 45) and 2.5 mg/kg of azathioprine; cyclosporine A (C5A)
was begun at the end of the mAb administration. At day 2 post
transplantation, the patient excreted 2 liters of urine; her serum creatinine
level decreased progressively to levels below 150 j.M (1.6 mg/dl) at day 9.
No adverse effect of the mAb was noted. Circulating trough levels reached
7 jsg/ml at day 6 and peaked at 11 jig/mI at day 11. No changes in white
blood cell counts were noted after an initial decline of 20% in lymphocyte
count. As early as day 3, LFA-1 site occupancy of the patient's lympho-
cytes by the antibody was saturated. In addition, patient-activated T-cells
had lost their capacity to bind a B-cell line bearing ICAM-1, the ligand of
LFA-1. An almost total modulation of the patient's CD11a molecule at
the lymphocyte surface membrane was found at the end of the treatment.
All these biologic effects disappeared by day 30.
The patient did not have any rejection episodes during the first 3
months after transplantation; her serum creatinine concentration was 130
jiM (1.4 mg/dl) at that time.
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Discussion
PROFESSOR JEAN-PAUL SOULILLOU (Director, Institut de Trans-
plantation et de Recherche en Transplantation, INSERM, Nantes,
France): Immunosuppressive drugs work by interacting with in-
tracellular molecules involved in many biologic functions. These
drugs include steroids, anti-nucleic acids (azathioprine, Brequi-
nar, ester of mycophenolic acid, desoxyspergalin), and anti-
transcription factors (cyclosporine, FK506, rapamycin). Milstein
and Kohler's pioneering work on cell hybridoma initiated the era
of monoclonal antibody therapy [see Ref. 1]. By recognizing a
single epitope on molecules expressed at the membrane of
immunocompetent cells, this immuno-intervention theoretically is
restricted to a subset of immunocompetent cells and possibly to a
specific biologic function and thus has considerably increased the
specificity of the immunosuppression.
Anti-lymphocyte reagents used in allograft transplantation were
first confined to rabbit anti-lymphocyte polyclonal gamma globu-
lins (ALG) [2], but now a growing family of potentially useful
monoclonal antibodies (mAbs) is available that recognizes a
variety of targets not solely on lymphocytes. The diversity of this
group of antibodies depends only on our knowledge of molecular
interactions at the immunocompetent cell surface. Although well
recognized as being effective in preventing and treating rejection,
ALG is associated with several disadvantages. These include
variability among batches, broad reactivity with antigens unrelated
to lymphocytes, and the occurrence of serum sickness. Therapy
with carefully selected monoclonal antibodies should circumvent
these problems, as mAbs have a single defined specificity, a
unique target, and are used at low dosage, thus virtually eliminat-
ing serum sickness. In addition, their effectiveness usually can be
followed through specific monitoring, as exemplified in the patient
presented and in Figure 1. The use of bioreagents in rejection
prophylaxis protocols is of primary importance in preventing the
recipient immune response during the first weeks after transplan-
tation. In renal transplantation, this approach allows the initiation
of cyclosporine A to be delayed until stable graft function is
obtained, with control of the immune response by the mAb at the
time of maximal risk of rejection. This approach usually is
associated with better functional results, increased patient com-
fort, and shorter hospitalization time [3]. However, a higher
incidence of viral diseases and lymphoma also has been encoun-
tered [4]. But a monoclonal antibody that has proved effective in
preventing graft rejection when administered as an induction
treatment is not necessarily successful in treating acute ongoing
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Fig. 1. Example of the monitoring of the effect of
an anti-CD11a in a human. Besides basic
pharmacodynamic information obtained from
the measurement of the monoclonal antibody
trough levels (U), other information specifically
related to the specificity of the mAb and the
function of the molecules recognized can be
studied, for instance, inhibition of T-B cell
adhesion (L) and CD11a site occupancy (•).
T-cell saturation by the mAb is expressed as the
difference in mean fluorescence intensity (A
MFI) when patient cells are labeled in vitro
with FITC-GAM with or without previous
incubation with an excess of 25.3 mAb.
rejection, as has been demonstrated for an anti-IL2R and an
anti-CD11a mAb [5, 6].
To date, only Orthoclone OKT3 (OKT3) has been used on a
large scale in the treatment (and later, prevention) of rejection in
human allograft recipients [7]. Many other monoclonal antibodies
directed at several different surface membrane molecules involved
in immune recognition are being actively explored in experimental
animals, and some of them are under study in pilot or randomized
clinical trials. In this Forum, I will focus on the mAbs already used
in the treatment of human allograft recipients. I also will briefly
discuss the new possibilities offered by some mAbs still under
study in animal models, as well as the new therapeutic tools
derived from monoclonal antibodies that have emerged from
molecular biologic techniques, such as chimeric or humanized
mAbs, or fusion molecules that comprise a part of the immuno-
globlin (Ig) structure.
Rationale for the choice of potential targets
Experimental data in animals indicate that therapeutic options
can vary according to the type of organ transplanted, the class I-
or class-Il compatibilities, and the magnitude of immunosuppres-
sion required by the clinical situation (for example, preimmuni-
zation). Therefore, different reagents are required to exert various
effects on the recipient's immune response and to act at different
steps.
Murine IgG monoclonal antibodies have poor and sometimes
undemonstrated in-vitro effector functions such as complement-
dependent killing, antibody-dependent cytotoxicity, and opsoniza-
tion. Thus, antibodies directed at "functional" surface-membrane
molecules have been preferred to those recognizing "structural"
targets, for example, anti CD7 [8—11], T12 or CD6 [12], or CBL1
antibodies [13], not primarily involved in immune recognition or
effector functions of immunocompetent cells. Furthermore, some
antibodies, highly specific for a function, by interacting with a
minority of immunocompetent cells, might gain in specificity and
produce fewer side effects by delivering inhibitory signals only,
without destroying their target (Table 1). The interpretation of
these data has been complicated by the observation that some
mAbs could induce tolerance rather than classic immunosuppres-
sion. Although this concept is extremely attractive, the salutary
Table 1. Specific versus nonspecific effects of monoclonal antibodies
Ligand/receptor inhibition
1L2/IL2R
ICAMILFA-1
Membrane modulation
CD3/CD4/CD7
LFA-1
Complement killing (isotype-related)
ADCC and promiscuous killing
CTL
Monocytes/macrophages
NK, CD16+ cells
Target opsonization
Apoptosis
state of tolerance has been achieved only in rodent allografts. In
this model, the tolerance state, as defined by a long-term accep-
tance of donor tissues with rejection of third-party tissues can,
however, be produced by different immune manipulations, includ-
ing pregraft donor blood transfusions [14], administration of CsA
[15], anti-ICAM/LFA-l [16], anti-CD4 mAbs [17], and may result
from efficient early immunosuppresion rather than from a specific
effect of the mAbs used.
Our ability to employ specific mAbs in vivo in animal models
and in some clinical trials is governed by our current knowledge in
the field of immune recognition and effector functions, especially
our understanding of the T-cell receptor complex, the growth
factor receptor involved in the clonal expansion of committed
cells, and adhesion and "second signal" molecules. These various
target families respond to different stimuli and have various
molecular interaction requirements; in some instances, the mAb
acts directly by modulating a ligand at the cell membrane (for
example, anti-CD3), whereas others act mostly as competitors for
soluble (for example, anti-IL2R) or membranous ligands (for
example, anti-LFA-1, anti-ICAM-1). In the last examples, the
epitope recognized is of paramount importance in achieving a
high degree of functional inhibition. The search for important
targets is not over and we are still in a phase of exploring
potentially interesting reagents (Fig. 2).
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Fig. 2. Examples of molecules used as targets of
monoclonal antibodies in immunosuppression in
vivo, or those of potential interest. From top to
bottom: receptors for T-cell growth factors
(1L2, 1L4, for instance) or for key factors in
inflammatory responses (IFNy); "second signal"
molecules such as CD28 or CTLA-4 and their
counter-receptors of the B7 family; adhesion
molecules such as 132 integrin (LFA-1), selectins(such as L-selectin on lymphocyte or E-selectin
on graft vessels) and beneath the T-cell
receptor; the CD2/LFA-3 couple. The
molecules (CD2/CD72) indicated at the bottom
of the figure are given as examples of targets
that could be used to specifically inhibit T-
helper/B-cell cooperation.
Anti-T-cell receptor complex
Anti-CD3 monoclonal antibodies. Orthoclone OKT3 [7] is a
mouse IgG2a directed against the 20 kD glycoprotein chain of the
CD3 complex (epsilon chain), which flanks the T-ceIl receptor
[see 18 for review]. First used in renal transplant patients by
Cosimi et a! in 1981 [19] and marketed in 1986, OKT3 is now
widely recognized as a powerful immunosuppressive agent that
reverses acute rejection [20] and is as effective as ALG in
protocols designed to achieve prophylaxis [21]. In these studies
[19, 20], OKT3 was given intravenously at a daily dose of 5 mg for
10 to 14 days, but lower doses (such as 22 mg over 10 days) have
yielded good results in induction protocols of renal transplanta-
tion [22]. Whereas high doses of steroids reversed 75% of acute
renal rejection episodes [7], OKT3 reversed 94% of acute rejec-
tion episodes; OKT3 also was effective in rejection episodes
resistant to steroids or ALG [23]. The effect of OKT3 on renal
function is somewhat delayed, however, occurring within 20 days
after the Onset of the treatment, and even longer in the case of
steroid- or ALG-resistant rejection episodes [22]. Recurrent
rejection episodes occur frequently (66% of patients) when OKT3
is administered without CsA [7] but only in 33% of patients given
CsA [24].
In protocols designed for prophylaxis, cardiac transplant recip-
ients treated with OKT3 experienced fewer acute rejection epi-
sodes during the first 3 months post transplantation than did those
treated with ALG (1,5 0.2 versus 2.2 0.2 rejection episodes
per patient) and required less chronic maintenance immunosup-
pression [25]. A randomized prospective trial in renal transplan-
tation showed that OKT3 and ALG produced similar results [26].
The OKT3 monoclonal antibodies interact only with T-lympho-
cytes and therefore are more specific than ALGs, which also bind
to monocytic, natural killer (NK) and B cells. In vitro, OKT3
inhibits both the generation of functional effector T-cells and the
activity of mature cytotoxic effector lymphocytes [27]. Peripheral
blood lymphocyte counts drop dramatically, but transiently, after
OKT3 administration, and reappearing T-lymphocytes fail to
express CD3 or T-cell receptors, whereas the other T-cell surface
determinants are normally expressed [28]. This modulation is
rapidly reversible after cessation of OKT3 or when patients are
immunized against the mAb. Accordingly, monitoring of OKT3
treatment can be based on measurement of the magnitude of the
decrease of the ratio of CD37CD2 circulating cells and, to a
lesser extent, on the measurement of the OKT3 plasma levels,
even though levels of 1 g/ml correspond to a concentration
that blocks T-cell functions in vitro. But OKT3 administration at
the usual doses does not always completely eliminate CD3 cells
in the graft [29], and changes in the local T-lymphocyte popula-
tions, with a shift toward an increase in CD8 and 2H4 cells,
have been reported [30].
The major problem associated with OKT3 is that severe adverse
side effects occur in a majority of patients, starting 45 to 60
minutes after the first two or three OKT3 injections and lasting for
several hours. These sequelae can include OKT3-mediated neph-
rotoxicity, with an average increase of 31% in serum creatinine
levels before improvement [31]. Pulmonary edema can be pre-
vented if any existing fluid overload is corrected before treatment
[7]. These side effects are related to the massive, although
transient, polyclonal release of cytokines such as TNFa, IFN7,
1L2, 1L3, and 1L6 [32] that occurs before CD3 modulation. Three
main, although not mutually exclusive, mechanisms could explain
this release of cytokines: (1) OKT3 causes opsonization, trapping,
and lympholysis of OKT3-coated cells by macrophages with a
subsequent release of cytokines; however, other anti-T-cell mAbs
(anti-LFA-1, -CD2, -CD4) do not provoke this phenomenon; (2)
OKT3 induces T-cell activation in vitro and in vivo; and (3) The
released lymphokines can, in turn, activate macrophages or,
alternatively, OKT3 can bridge T-lymphocytes and macrophages/
monocytes, which also results in their activation [33]. The side
T cell APC
or
target cell
MHCTCR i) CLI. CLII
CD5 I CD72
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effects are reduced by the administration of a high dose of steroids
(a bolus of 0.5 to 1.0 g methyiprednisolone intravenously one hour
before injection [34]); this maneuver inhibits production of cyto-
kines but can contribute to over-immunosuppression and con-
found assessment of the effect of the monoclonal antibody. The
finding that anti-TNFa mAbs also decrease OKT3's side effects in
mice and in humans confirms the major involvement of TNFa in
this syndrome [35]. Beside their role in OKT3-induced first-dose
reactions, cytokines released after OKT3 injection also might be
involved in the immunosuppressive properties of the antibody.
Indeed, OKT3 in humans and a similar anti-CD3 antibody in mice
induced IL-b, a cytokine with potent immunosuppressive and
antiinfiammatory properties [36, 37].
Although no serum sickness is observed following the use of
OKT3, the xenosensitization can totally abrogate the mAb's
effectiveness. Recipient anti-OKT3 (1gM and IgG) of both anti-
isotype and neutralizing anti-idiotype specificities are usually
produced [38]. The incidence of anti-OKT3 antibodies decreases
with the use of associated immunosuppressive treatment: 70% to
100% immunization was reported when OKT3 was used alone [7],
compared with 25% when OKT3 was given in association with low
doses of steroids and azathioprine [39], and with 15% when
steroids and azathioprine were combined with CsA, the latter
given at 50% of its usual maintenance dose [24].
The incidence of infectious disease does not differ between
OKT3 and ALG therapy [26], but this incidence did increase
significantly when OKT3 was compared with conventional immu-
nosuppressive drug treatment [40]. Finally, two reports show that
prolonged use (or re-use) of OKT3 must be avoided because it has
been associated with a dramatic increase in lymphoproliferative
disorders in cardiac transplantation (36% in patients who received
more than 75 mg versus 6% of patients who received less than 75
mg) [41, 42].
Several other monoclonal antibodies directed against CD3 or
against T-cell receptor monomorphic epitopes have been tested in
human renal transplantation. While these newer anti-CD3 mono-
clonal antibodies did not significantly reduce cytokine release [43],
progress may come from using mAbs against the monomorphic
determinant of a/3 chains of the T-cell receptor [44], which can
reverse acute rejection episodes and yield fewer and less severe
side effects than expected. The use of this anti-T-cell receptor
monoclonal antibody is associated with an absence of in-vitro
mitogenic effect; the antibody does modulate the CD3-T-cell
receptor complex at the T-lymphocyte surface. Another anti-a13
chain T-cell receptor mAb (BMA 031, a murine IgG2b) was also
studied as prophylaxis but was ineffective at the tested dose [45].
Another approach uses the F(ab')2 fragments, which neither
cause T-cell activation nor increase animal morbidity or mortality,
but which prolong the survival of skin allografts [46]. Molecular
biologic techniques also can produce variable immunoglobulin
fractions (scFv) [47]. Although OKT3 F(ab')2-digested fragments
are markedly less potent T-cell activators in vitro than is whole
mAb, no one has demonstrated in humans that monoclonal
antibody fragments are effective.
Antibodies against adhesion molecules
A rapidly growing list of molecule families playing a role in
cell/cell adhesion—including immunocompetent cell interrela-
tionships and immunocompetent cells/allogeneic target interac-
tions—has been described [see 48—50 for reviews]. Although
usually ubiquitously distributed, some adhesion molecules are
more restricted to bone marrow white cell lineage (such as
LFA-1) or, even more specifically, to a single cell interaction, such
as ELAM [51]. These molecules therefore are involved in a variety
of basic biologic events, including embryo development, tissue
repair, and immune function. Elegant studies have shown that
dynamic leukocyte/endothelial cell interactions are regulated by
several specialized receptor/ligand couples that operate in succes-
sive steps; these steps encompass a number of processes from
induction of leukocyte rolling on endothelial cells to their immo-
bilization, processes that allow immune effectors to act on endo-
thelial cells or to leave the vascular compartment through the
endothelial layer [51]. Agents that can block these receptor/ligand
interactions also might interfere with immune recognition and
effector functions. Furthermore, indirect experimental evidence
suggests that adhesion molecules also could play a role in
nonspecific white-blood-cell-related lesions of endothelial cells
during the revascularization syndrome of transplants [52]. Exper-
imentally, antibodies directed against adhesion molecules such as
anti-CD2 [53], anti- LFA-1, and anti-ICAM-1 [16] have delayed or
reversed graft rejection. Furthermore, an anti-CD1 la associated
with an anti-ICAM-1 can induce tolerance in rodents [16].
Among the adhesion molecules, those of the /32 integrin family,
including LFA-1, are involved in the late adhesion process. They
are composed of two non-covalently linked polypeptide chains
[for review see 48]. Three different subfamilies are defined by 3
different a chains. The /3 chain, or CD 18, can associate with these
3 different chains (CD11-a-b-c) to constitute the LFA-1, Mac
1/CR3, and p150/95 molecules, respectively. These 3 molecules
are expressed on leukocytes only, whereas their ligands, ICAM-1
(CD54), -2, and -3 for LFA-1, are widely distributed. ICAM
molecules are present on endothelial vascular cells, macrophages,
monocytes, and activated B lymphocytes [48]. ICAM-1 is up-
regulated by TNFa, 1L4, and IFNy and can also be induced on
fibroblasts, keratinocytes, and epithelial cells. LFA-1 was first
defined by anti-CD11a mAbs, which inhibited cell-cell adhesion
and several effector functions in vitro: cytotoxic T-lymphocyte
(CTL)- and NK-mediated lysis, T-B cell cooperation leading to
antibody production, and interactions between T/monocytes and
T/vascular endothelial cells [51]. The cellular adhesion in which
LFA-1 is involved enhances T-cell receptor/antigen recognition,
and provides auxiliary signals for T-cell activation. T-cell activa-
tion also increases cell "adhesiveness" through conformational
changes of the LFA-1 molecule. In humans, clinical studies using
anti-LFA-1 have been conducted mostly in bone marrow trans-
plantation. Congenital absence of LFA-1 is associated with a severe
immune deficiency, suggesting that interfering with this molecule
could also result in strong immunosuppression [54]. Fischer et al
successfully used a mouse anti-CD11a (25—3; IgGi) in children who
had undergone a bone-marrow transplant to prevent the rejection
of HLA-mismatched marrow [55]. Another pilot study, however,
failed to reproduce this result in leukemic adults receiving a
T-cell-depleted bone marrow transplant, with the same mAb [56]
or with an anti-CD18 mAb (/3 chain) [57]. The anti-LFA-1, mAb
25—3, also has been used in our center to attempt to reverse
first-time acute rejection episodes in 7 recipients of a first-kidney
transplant who were taking cyclosporine and azathioprine [6].
This anti-CD11a mAb, which produced only a few side effects, was
not effective in 6 of the 7 patients treated, although circulating
levels of mAb 25—3 were at concentrations 3- to 12-fold higher
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than the mAb dissociation constant (lCd —5 nM); this lack of
effectiveness thus was not a consequence of low drug concentra-
tion. Interestingly, only one patient of the 7 developed anti-25--3
IgG at day 17, albeit low levels; this observation is consistent with
experimental studies [58]. The low incidence of antibodies against
mAb 25—3 might be related to the in-vitro ability of anti-CD11a to
interfere in the cell-cell interactions leading to antibody produc-
tion; interference with antibody production could be more sensi-
tive to mAb 25—3 than the cellular events involved in acute
rejection. Although attempts at treating acute cellular rejection
episodes with anti-CD11a in renal transplantation have been
unsuccessful, results obtained in bone marrow transplant recipi-
ents suggest that further studies might prove useful, particularly in
prophylactic protocols.
Indeed, although inadequate in treating ongoing rejection
crisis, the 25—3 anti-CD11 monoclonal antibody has been ex-
tremely encouraging when given prophylactically in patients re-
ceiving their first renal transplant. In a phase-I study of 15 patients
receiving escalating doses (10 to 20 mg/day, administered for the
10 days following transplantation) in the absence of cyclosporine
A, we have observed no rejection crisis during the first 30 days
[59]. Administration of the anti-CD11a was associated with a full
occupancy of the CD11a site, even when used at the lowest dose
studied (10 mg/day) and with an impaired adhesiveness of the
patient's T-cells for Daudi B cell line (ICAM-1) cells (Fig. 1). In
addition, disappearance of the bright component of the classical
bimodal membrane expression (bright/dim) was found at the end
of the treatment, indicating CD11a (as well as CD18) membrane
modulation. Only 3 of 15 patients were immunized, and the
anti-mouse titers were remarkably low [59].
A mouse IgG2 antibody directed against one of the three
ligands of LFA-1 (ICAM-1), R6.5, also has been tested in kidney
and heart transplants; in cynomolgus monkeys, R6.5 delayed and
reversed acute interstitial rejection [60]. In this study, the anti-
ICAM-1 monoclonal antibody triggered an immune response in
the primate and, although the renal endothelial cells of the
treated animals were covered by the mAb, graft function was
unimpaired and histologic examination did not show vasculitis.
The same mAb was recently used in a pilot study in human and
hyperimmunized recipients, or in patients having received a
kidney with a long ischemia time. Although the number of
patients in whom the mAb reached significant circulating levels
was low, the incidence of acute rejection (2/7), as well as of
delayed graft function, suggests that the interaction with either the
receptor or ligand of the LFA-1/ICAM couple prevents allograft
rejection [61]. Would the combined use of anti-LFA-1 and
anti-ICAM induce a tolerance state, as in the mouse model [16]?
Despite these promising pilot studies, clinicians fear the poten-
tial for severe infection, and only larger trials will allow a more
definitive conclusion. Clearly, these extended trials also will have
to veri' whether inhibiting the relevant epitope involved in
ICAM binding to LFA-1, and therefore its interaction with all of
its 3 ligands, will be a better strategy than interfering with
ICAM-1, which is only one of the redundant ligands of LFA-1.
Theoretically, both anti-LFA-1 and anti-ICAM-1 should equally
prevent ischemia-related damage unless a further redundancy of
an unknown LFA-1-ligand surrogate exists. A possible effect on
delayed function in the anti-CD11a pilot study might have been
missed in our trial, owing to the fact that this effect, suggested by
the first pilot study with anti-ICAM-1, was noted only in recipients
with long ischemia time, whereas short ischemia time was com-
mon in our study. Interestingly, a recent report, demonstrating
that inhibiting another adhesion molecule (P-selectin) decreases
white-blood-cell-related lesions [52}, suggests a need for a deeper
exploration of the effect on ischemia-related graft damage of
antibodies (or soluble ligands) interacting with various adhesion
molecules.
Another potential adhesion/activation target is the CD2. Anti-
bodies have been successfully tested in vivo [53], and a clinical
trial in which anti-CD2 antibodies are associated with anti-CD11a
is currently underway in the prevention of mismatched bone-
marrow grafts (Fisher A, personal communication). A 50—55 kD
glycoprotein expressed by mature T-lymphocytes and NK cells in
humans, CD2 contributes to increased T-cell adhesiveness to
LFA3-bearing cells. The CD2/LFA3 interaction also provides
co-signals that increase the antigen-specific signal, as shown by
bispecific antibodies or by the use of a combination of certain
anti-CD2 mAbs in vitro [62j. Futhermore, activation through CD2
increases LFAI-ICAM interaction [63]. In animals, anti-CD2
mAbs produced cell unresponsiveness and prolonged pancreatic
islet grafts (both in naïve and immunized recipients) [64] and
cardiac allografts [53]. Furthermore, a combination of an anti-
CD2 and anti-CD3 results in the induction of a tolerance state
[65]. A fusion protein between LFA3 and the constant part of IgG
heavy chain can prolong allograft transplantation in monkeys
through a mechanism that involves CD16 cells (Hochman PS,
Chisholm P, Marboe CC, et al, unpublished observations). Thus,
experimental evidence clearly shows that blockade of the CD2-
LFA3 couple is promising in immuno-intervention.
Antibodies against co-stimulatory and co-receptor molecules
T-cells recognize "antigen" as peptides originating from the
processing of intracellular (presented by class-I MHC molecules)
or from membranous and internalized exogenous structures (pre-
sented by class-Il MHC molecules). Optimal T-cell receptor
interaction with the HLA/peptide complex (direct or indirect
presentation of graft antigens) requires, however, the presence of
other families of molecules [see 66 for review]. These families
include co-receptor molecules, CD4 and CD8, which bind to
different domains of class II and on an epitope of the 3 region of
class I, respectively; adhesion molecules (such as LFA-1); and
"second signal" molecules, such as CD28 or CTLA-4 [67]. All
these molecules interact with their corresponding specific ligands
at the membrane of presenting cells (MHC, ICAMs, and B7,
respectively). Their presence can result in a restricted recognition
(CD4 for class-Il, and CD8 for class-I presentation, for instance),
in increased cell/cell adhesiveness and avidity (LFA-1, for in-
stance), and in the production of transcription factors for a variety
of cytokines. These cytokines in turn will further induce a self and
paracrine promotion of genetically committed T-lymphocytes, as
for instance after interaction between B7 and CD8-CTLA-4 [67].
Other molecules are more specialized in T-helper—B-cell interac-
tions, such as CD5 (on T-helper cells), which interacts with CD72,
a specific B-cell ligand [50]. However, since the engagement of
both co-receptors and adhesion molecules with their ligands have
been shown to deliver co-stimulatory signals per se, and since
"second signal molecules" such as CD28 do require cell/cell
contact for transcriptional activation, the restricted terminology
commonly used oversimplifies their dual effect, adhesion as well
as stimulation.
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The understanding of the various steps controlling T-cell acti-
vation opened new possibilities for immuno-intervention through
the use of specific inhibitory monoclonal antibodies. Indeed, an
antigen-presenting cell that does not express one of these mole-
cules or that interacts with committed T-cells in the presence of a
blocking antibody (which interferes with one of these receptor!
ligand couples) will not optimally present antigen. In addition,
new molecular tools such as truncated receptors or ligands
(soluble CTLA-4 or ICAM-1, for instance) fused (or not) with the
constant part of an IgG heavy chain have been successfully used
and thus may represent alternatives to monoclonal antibodies
[68]. But although the possibility of interfering with immune
responses through the inhibition of accessory molecules has been
actively explored in animals, only anti-CD4 has been used in
clinical trials.
During antigen recognition by T-cell receptor, CD4 molecules
on T-cells bind class-Il molecules on presenting cells, increasing
cell/cell interactions and delivering co-stimulatory signals. CD4 is
a monomeric 55 kD glycoprotein that can associate with the
56K (a tyrosine protein kinase [69]); antibody-mediated cross-
linking of CD4 results in increased tyrosine phosphorylation and
kinase activity of P56LcK controlled by CD45 [70}. Engagement
of CD4 before T-cell receptor cross-linking also can result in cell
death by apoptosis. Several CD4 mAbs are available in various
species. Encouraging results have emerged from their use in
manipulating models of experimental organ transplantation in
rodents and primates. In rodents, anti-CD4 mAbs given before
grafting induced a state of donor-specific unresponsiveness [see 17
for review]. Second grafts from the same donor strain were
prolonged, whereas acute rejection of a third-party graft was
observed [71, 72]. Concomitant injection of soluble antigen and
anti-CD4 mAb [or F(ab')2 fragments] results in a specific, long-
lasting unresponsiveness to subsequent initial antigen challenges
[73]. As donor-specific blood transfusions can also induce specific
hyporesponsiveness to a subsequent organ allograft, combined
treatment with donor antigen and anti-CD4 niAbs administered
several weeks before transplantation has resulted in an indefinite
acceptance of allografts in mice [17]. Induction of the unrespon-
siveness state was accomplished only at optimal donor-blood
transfusion volume and mAb dosage. In this model, F(ab')
fragments given at a high dose (times tenfold) also were effective,
whereas perioperative injections of the mAbs were less effective
than when administered weeks before grafting [17]. The mecha-
nisms responsible for the tolerance induced by anti-CD4 mAbs
remain unclear. More information is required regarding the
relevance of various epitopes at the CD4 molecule recognized by
the mAbs [74], as well as that of the depleting and/or modulating
capacity of a given mAb. After administration of a large dose of a
depleting antibody, the tolerance state that follows the nonspecific
immunosuppression might result from the emergence of T-cells
that have matured in a new environment (that is, in the presence
of graft antigens), thus resulting in specific inactivation of a T-cell
clone against the alloantigens. Furthermore, CD4 splenocytes
from tolerant mice administered with an anti-CD4 mAb actively
transfer the specific unresponsiveness state to naïve syngeneic
animals [75]. Anti-CD4 mAbs also have been reported to be
poorly immunogenic; this finding suggests that they could induce
self-tolerance [58].
Post-graft treatment by OKT4A or a mixture of two anti-CD4
mAbs (OKT4 and OKT4A) in rhesus monkeys prolongs renal
graft survival [76]. Several preliminary reports in humans have
appeared; the first study used BL4 antibody (IgG2a) administered
from day 3 to 14 after transplantation [77]. Although this series
was too small to allow any definitive conclusions regarding BL4's
effect on early rejection (4 episodes in 12 patients), only one
patient developed anti-BL4 antibodies; some anti-CD4 antibodies
probably thus can mimic in humans what has been observed in
mice [58]. A non-depleting, non-modulating IgG2a, OKT4A was
used prophylactically (8—12 days at 0.2 mg/kg/day) in 6 patients,
along with a triple induction protocol. Although all patients
experienced acute rejection within 6 weeks (3 during OKT4A
treatment), no firm conclusion can be drawn because the dosage
and timing of OKT4A were not pharmacokinetically optimal [78].
Interestingly, whereas this dose of the mAb was highly immuno-
genic in humans, a humanized chimeric OKT4A (IgG4) triggers
no reactivity in non-human primates [79].
We have just completed a study of a murine IgGl directed
against the second domain of CD4; the antibody was administered
in 14 patients for 10 days after renal transplantation (unpublished
observations). This mAb transiently depletes CD4 cells and
modulates CD4 molecules at the cell membrane. The mAb was
not associated with any anti-CD3-like side effects and did not
produce a tolerance state; 4 patients experienced acute interstitial
rejection shortly after cessation of the mAb. Thus, although the
use of blocking, or transiently depleting, anti-CD4 might be
somewhat effective and possibly introduces a level of specificity in
the treatment of graft recipients, preliminary experience does not
suggest that tolerance is achieved in monkeys or humans following
anti-CD4 administration. The data are far from conclusive, how-
ever. For instance, clinical trials are restricted to administration of
anti-CD4 shortly after transplantation or immediately postopera-
tively; these conditions favor nonspecific immunosuppression
rather than specific tolerance. In experimental animals, donor-
specific suppression occurs only several weeks or months after
anti-CD4 administration [17].
In addition, immuno-intervention through CD4 manipulation is
confounded by hazards inherent to the complexity of mechanisms
of the CD4-mediated effect in allorecognition. First, the respec-
tive involvement of CD4 versus CD8 populations depends highly
on the expression of either class-I or -II MHC molecules on the
graft, the pre-immunized or naïve status of the recipients, and the
kinds of grafted tissue; inhibition of the CD4 subset thus might
not always be adequate. Our current understanding of the mech-
anisms of action of anti-CD4 is probably simplistic. We perceive a
decrease in the affinity of the CD4 cell in immune interaction
that results from the administration of blocking, modulating, or
depleting anti-CD4, and a subsequent impairment in helper T-cell
function. But peripheral blood depletion is not always associated
with a significant lymph node or thymic depletion [17]. Further-
more, in mice treated by an anti-CD4, a peripheral anergy has
been evidenced in alloreactive cells identified by monoclonal
antibodies (V5 Vf31 1k); however, the co-administration of
anti-CD8 prevented the development of anergy of V135 V/311 cells
without blocking the tolerance against the allogeneic islet cells
used in this model [80]. Also, helper memory cells and the TH2
population producing IL1O and 1L4 escape anti-CD4 therapy in
rodents [81], whereas only few 1L2-producing cells were found.
This profile suggests an imbalance in TH1/TH2 reminiscent of
that reported in donor-cell-injected cardiac graft recipients [82].
Although CD4 manipulation is extremely promising, we need to
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further understand its mechanism of action and its role in the
treatment of patients undergoing renal transplantation.
Monoclonal antibodies against interleukin 2 receptors
The availability of antibodies directed at activation determi-
nants induced on the genetically pre-committed lymphocyte sub-
set, such as mAbs targeting 1L2-receptor (IL2R), offers a new
possibility for more selective immunosuppression. Resting T-cells
neither express the a(P55) low-affinity component of IL2R nor
the functional high-affinity IL2R. Following antigenic stimulation
through the T-cell receptor, specific T-lymphocytes are activated,
1L2 is secreted, and functional IL2R is transiently expressed [83];
this process allows antigen-committed lymphocytes to expand. At
least three polypeptide chains contribute to the formation of the
functional IL2R. The a or Tac chain was the first component
recognized; this 55 kD glycoprotein is the antigen-inducible
structure of the system and, after antigenic stimulation, its expres-
sion increases by at least 10 times. This chain alone has a low
affinity for 1L2 (Kd 20 nM) [83] and is not able to internalize 1L2
[84]. The 75 kD J3 chain has an intermediate affinity for 1L2 and
is required to internalize 1L2. The 13 chain, needed to optimize
signal transduction, is also present on resting T-lymphocytes and
natural killer cells. After antigenic a chain induction, approxi-
mately 10% of a chains associate with the 13 chain and form the
high-affinity IL2R (lCd 30 pM) [85] in the presence of a third
component, the recently characterized gamma chain [86]. The
gamma chain is involved in the high-affinity conformation as well
as in the signal transduction; specific mutations of this gamma
chain, which is shared by 1L4 and 1L7 receptors [87], result in
severe congenital immunodeficiency in humans [88].
As P55 contributes to the high-affinity complex, mAbs directed
at the 1L2-binding site of the a chain are potent inhibitors of
1L2-driven proliferation. Their presence, in sufficient amounts to
block 1L2-binding, therefore should result in the specific inhibi-
tion of the growth of the pre-committed recipient cells activated
by foreign antigens. Theoretically, this approach spares the resting
T-cell repertoire. But the recipient's immune response against any
other T-cell-dependent antigens introduced into the recipient
during anti-IL2R treatment also will be depressed. Interleukin 2
has been well documented as a major pivotal growth factor for
T-lymphocytes; however, it is likely that other lymphokines can
substitute for 1L2. Verification comes from studies of animals in
which the 1L2 gene has been disrupted by homologous recombi-
nation [89] and which can still mount some T-cell response. Both
1L4 and 1L7 are potent T-cell growth factors that can partially
replace 1L2. However, antibodies directed against IL2R are highly
effective in a variety of animal models and in humans. In the
mouse, treatment for only 10 days produces indefinite graft
survival in more than 50% of recipients [90]. In the rat, anti-IL2R
antibodies are effective as single agents and also act in synergy
with cyclosporine [91]. A mice anti-human a chain of IL2R
(anti-Tac) allows the prolongation of renal allografts in cynomol-
gus monkeys [92].
We have used a rat IgG2a mAb (33B3.1), which inhibits IL2
binding on both P55 and high-affinity IL2R, and which blocks
IL2-driven proliferation [93, 94], to determine its effect in kidney
transplant recipients [95]. To date, we have given this mAb to 135
recipients of first or second renal or renal/pancreas transplants.
Almost all recipients tolerated the 33B3.1 well. Although a dose
of 5 mg/day was insufficient to obtain "therapeutic" trough levels,
10 mg/day produced a trough level of approximately 4 sg/ml and
gave encouraging results in a preliminary study on the prevention
of acute rejection episodes [95]. We gave the mAb immediately
after transplantation and for 2 weeks thereafter along with
corticosteroids and azathioprine.
We subsequently conducted a prospective, randomized, con-
trolled trial [96]. One hundred consecutive recipients of primary
cadaveric renal transplants received either 33B3.1 (n =50) or a
rabbit ALG (n = 50). The 33B3.1 was given at 10 mg/day in the
first 2 weeks after surgery with 1 mg/kg of methylprednisolone and
2 mg/kg of azathioprine; at the end of the mAb course (day 14),
CsA was started. Only one patient treated with 33B3.1 required
that the drug be stopped because of major clinical intolerance,
versus 16 (32%) patients in the ATG group. A similar number of
rejection episodes occurred during the first 3 months (15 versus 12
in the 33B3.1 and ALG groups, respectively). However, the
33B3.1-treated recipients experienced more rejection episodes
during the first 2 weeks (6 versus 1). Between months 4 and 12
after transplantation, 7 patients in the ALG-treated group expe-
rienced a total of 9 rejection episodes versus 3 patients with 3
rejection episodes in the mAb group (NS). After the first year, the
incidence of rejection episodes was 5% in both groups of patients.
Fewer episodes of infectious disease occurred in the 33B3. 1 group
(47 versus 72); possibly the activated T-cell specificity produced
more specific immunosuppression. Regarding viral infections (in
which T and NK cells have been mostly involved), 8 of the 9 cases
of cytomegalovirus disease in the mAb group were mild, while half
(5 of 10) were severe in the ALG-treated group. After three
months, the number of infectious episodes remained lower in
patients who received the mAb as compared with those treated
with ALG (9 versus 23). A strong immunization against rat IgG2a
occurred in 80% of patients receiving 33B3.1, thus significantly
lowering circulating mAb levels.
Less-favorable results have been obtained in two additional
studies conducted in repeat renal transplantation [97] and in
simultaneous renal/pancreatic transplantation [98]. In second
renal transplant recipients, 33B3.1 was given for the first 10
postoperative days in association with steroids and azathioprine
(CsA was started at day 10). Similar patient and graft survival
rates were observed at one year (77% versus 71% in ALG and
33B3.1), and an equal incidence of rejection episodes occurred
with both regimens (45% and 44%). Rejection was more frequent
(40% versus 0% in the ALU group) during the 10 days of therapy
with the monoclonal antibody, however, despite high circulating
trough levels. Almost all recipients were sensitized by 33B3.1. In
double graft recipients, CSA was associated with 33B3.1 for the
first 10 days. No rejection occurred during the 10 days of
treatment in these patients. Later, episodes of kidney rejection
were more frequent in the 33B3.1-treated patients. All these
diabetic recipients had received grafts without tissue matching.
Patient survival was 83% and 100% in the ATG and 33B3.1
groups, respectively.
Because the 33B3.1 was effective in preventing rejection epi-
sodes and anti-IL2R could reverse ongoing rejection in animals,
we initiated a pilot study to assess the effect of this mAb in the
treatment of 10 initial, acute interstitial rejection episodes in first
kidney grafts [5]. Six episodes partially responded to treatment
and 4 required rescue treatment. During ongoing rejection epi-
sodes, the effector T-cells had already proliferated, expanded
within the transplant, and recruited inflammatory cells. At that
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time the effector mechanisms resulting in rejection are no longer
restricted to activated T-lymphocytes, which are the primary
targets of anti-IL2R.
Other clinical trials have been performed following renal
transplantation with different anti-P55 mAbs, Kirkman and
colleagues reported a randomized trial of anti-Tac (murine
IgG2a against P55 chain) in human renal transplantation [99].
As we did, they gave anti-Tac mAb as induction therapy along
with steroids and azathioprine, but CsA also was added. Their
results suggest that anti-Tac decreases early (first month)
rejection episodes in renal allografts. Other studies have shown
the efficacy of a rat mAb, IgG2b (LO-Tac-1), and a mouse IgGi
mAb (BT563), in renal and liver transplantation [100, 101]. The
literature appears to confirm that blocking 1L2 binding results
in successful allotransplantation. But it is too early for us to
conclude that this approach also will be beneficial in trans-
plants performed in hyperimmunized patients or on second
grafts. The availability of "humanized" mAb [102], and the use
of mAb combinations [103] or bispecific mAb [104] might
further enhance the efficiency of anti-IL2R. Nevertheless,
anti-IL2R currently is probably the most promising bioreagent
in prophylactic therapy for first-kidney grafts, owing to its
absence of side effects and higher specificity.
Antibodies directed against cytokines themselves also have
been tested in animals. The theoretical advantage of such an
approach would be high biologic specificity; however, the local
range of activity of most of the cytokines, and the stoichiomet-
nc ratio of ligand/receptor, might explain the dearth of reports.
Other targets, monoclonal antibody combinations, and
engineered reagents
A variety of monoclonal antibodies directed at epitopes present
on resting or activated T-cells—or with wider distribution—also
has been used experimentally and sometimes clinically. These
mAbs belong to a heterogeneous group including anti-CD52,
anti-CD45, and antibodies directed against yet-unknown specific-
ities.
Campath-1. The family of Campath-1 antibodies comprises rat
mAbs of various isotypes, including 1gM as well as a chimeric
human IgG. These mAbs recognize a phosphatidylinositol-
anchored antigen (CD52) expressed on virtually all white blood
cell lineages [105]. Campath-1 binds human complement [106]
and effectively purges bone marrow of T-cells through human-
complement-mediated cytotoxicity. Campath-1 has been evalu-
ated further in a randomized trial in 52 renal allografts [107]. The
protocol compared Campath-1 (25 mg/day for 10 days) and high
doses of CsA (17 mg/kg) with high doses of CsA alone. The
incidence of rejection episodes was lower in the mAb group;
however, major infection episodes significantly increased after
mAb treatment. The anti-rat immunoglobulin antibodies, detect-
able on day 10, further increased during the following 7 days.
Other 1gM inAbs. Although the use of Campath-1 seems attrac-
tive when compared with polyclonal anti-lymphocyte globulins,
this approach carries the risk of over-immunosuppression, a
problem difficult to assess because the mAb was administered with
high doses of CsA [106]. The effectiveness of this monoclonal
antibody is likely related to its capacity to bind human comple-
ment. Thus 1gM mAbs probably act more via their isotype-linked
properties rather than by interacting with a molecule exclusively
involved in alloimmune recognition.
Accordingly, several groups have followed the same approach
of using a monoclonal antibody of the 1gM isotype in an attempt
to increase effector function. Takahashi et al first used the CBL1
mAb (a mouse 1gM) directed against a determinant present on
human lymphoblast cells [13]. They administered the CBL1 mAb
at 5 mg/day for 9 days in acute steroid-resistant rejection episodes.
The mAb was beneficial in 50% to 90% of the episodes [108].
Despite these promising initial studies, results concerning prophy-
lactic utilization of CBL1 in allograft recipients of living-related
kidneys were inconclusive [109].
Another 1gM, the CHAL 1 monoclonal antibody (anti-T and -B
cells and anti-monocytes), was tested at 12 to 24 mg daily doses
over 9 days in 28 renal graft recipients undergoing acute cortico-
steroid-resistant rejection episodes (4 living-related grafts, 18 first,
and 6 second cadaveric grafts) [108]. Fourteen cadaveric graft
recipients received CsA and prednisone; the others received
prednisone and azathioprine. The reversal rate was higher among
CsA-treated patients than among azathioprine-treated patients
(81% versus 50%), but 33% of the patients treated with CHAL1
had rejection recurrence in this preliminary report [108].
Anti-CD45. Also of 1gM isotype, this monoclonal antibody has
been used to eliminate passenger leukocytes within allografts,
particularly the interstitial cells of bone marrow origin, which are
believed to play a major role in the "direct" pathway of presen-
tation of donor-specific antigens to the recipient lymphocytes.
This mAb is directed against a widely expressed CD45 isoform
present on almost every white blood cell lineage (a protein
tyrosine phosphatase that is produced as additional forms from a
single gene by alternate splicing). Ex vivo, anti-CD45 treatment of
renal grafts produces a high degree of coating of CD45 cells and
significantly decreases the incidence of subsequent rejection (18%
versus 63%) [110]. The availability of a monoclonal anti-pig CD45
has allowed the same group to better assess the ex-vivo perfusion
conditions and reach a CD45 labeling rate of at least 95%.
Anti-CD7 mAb. Anti-CD7 monoclonal antibodies recognize a
40 kD antigen present on T-cells and preferentially on T-cell
blasts [111]. A chimeric anti-CD7 mAb derived from the RFT2
hybridoma [9] has been studied as a prophylactic regimen in renal
allograft patients. The mAb was well tolerated, induced a modu-
lation of the CD7 molecule, and did not trigger anti-mAb host
antibodies. Further, the mAb's ability to prevent early rejection
was encouraging [10].
Monoclonal antibody combinations and bifunctional antibodies.
Although combinations of mAbs recognizing synergistically active
molecules have been shown to be more potent in inhibiting some
immunologic functions in vitro than when used alone, in-vivo
experiments have been limited so far. In recipients of mismatched
bone marrow, a slight beneficial effect on rejection was observed
in patients receiving anti-LFA-1 and an anti-CD2 (Fisher A,
personal communication). The combination of anti-LFA-1 and
anti-CD2 has proved highly effective in inhibiting mixed lympho-
cyte response (MRL) in vitro (BOhmig GA, personal communi-
cation). There are, in addition, several other examples in which
combinations of two mAbs are attractive. For instance, 33B3.1
antibody cannot block 100% of 1L2- (or mitogen)-induced prolif-
eration of alloreactive clone in vitro, whereas when 33B3.1 is
combined with a second mAb directed to IL2R 13 chain, the
proliferation of the 1L2-induced clone, as well as 1L2 binding, are
almost completely inhibited [103]. This finding suggests that the
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combination would increase the effectiveness of anti-IL2R ther-
apy. Interestingly, it is the combination of two antibodies directed
at epitopes carried by independent targets such as ICAM and
CD11a [16] or CD2 and CD3 [65] that has been able to achieve
tolerance in animals, whereas the administration of a single mAb
was ineffective.
Another way of combining the effect of two mAbs displaying
potentially synergistic functions is preparing bispeeifie antibodies.
Keeping with the IL2R targeting example, bispeeifie antibodies
carrying both anti-P55 and anti-P75 specificities are highly effi-
cient in inhibiting 1L2 binding and IL2-dependent proliferation in
vitro [104]. Although it is difficult to conceive that clinicians will
soon have the opportunity to demonstrate as clinically valuable all
the theoretical possibilities of intervention using mAbs, bifunc-
tional antibodies also could be used to increase the targeting
efficacy to a given molecule if one of the specificities is devoted to
CD3 recognition [112]. This dual recognition will result in the
killing of cells that have been brought into the CD3 + cell vicinity
by the second specificity of the bifunctional killing.
Conclusion
Although only partially explored in animals and having re-
stricted application in humans so far, the use of monoelonal
antibodies in transplantation has opened up a large field of new
possibilities. However, the high clinical cost of this approach will
no doubt limit the study of many mAbs. In many instances (for
example, anti-CD4) different results may arise from the use of
antibodies that recognize distinct epitopes on the same molecule;
this situation will render unpredictable the effect of some mAbs in
humans. Furthermore, some degree of the species specificity in
the immune response (as well as variations in the pattern of target
distribution between humans and animals) can make even more
difficult the extrapolation of the usefulness of an antibody active in
animals to the clinical setting. Finally, the paradigm of an
exclusively specific intervention on the immune system is tem-
pered in practice by the role of the constant parts of the
antibodies—and of their corresponding isotypes—that will be
even more important in "humanized" reagents. Indeed, "optimal"
constant part-related effector functions (for example, comple-
ment-fixing isotypes) can result in cell destruction with a de-
creased specificity of action. Therefore, working hypotheses based
on specific targeting of key molecules at the membrane of
immunocompetent cells might be fundamentally biased except for
targets expressed on highly restricted cell subsets (such as the 1L2
receptor). For target molecules more widely expressed, effector
mechanisms aimed at a specific intervention should work through
membrane modulation of the molecule or specific competition
with the corresponding ligands. Although molecular engineering
of the mAb can favor either alternative—strict molecular target
specificity by the use of scFv fragments for instance [47], or
"optimal" constant region by the choice of the adequate isotype—
the final relevance of the "target effect" still depends on all these
factors.
Questions and answers
DR. NIcoLAos E. MADIA5 (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): What is the best
available explanation for the marked release of cytokines after
OKT3 administration but not after treatment with other anti-T-
cell mAbs? Is it a difference in cytolysis or in T-cell activation?
DR. SouLILLou: It seems that the magnitude of the side effect in
vivo correlates with the proliferative signal delivered in vitro by
the anti-CD3. The differences likely are due to the isotypes of the
mAb that control Fe-related functions. The in-vivo side effect will
then depend on the capacity of the mAb to bridge the monocytes
and macrophages that activate T-eells. Some recipients have fewer
side effects than do others because they express Fe-receptor
polymorphism. Some Fc species do not interact with Igi or Ig2b
mAb for instance [113]. In this last case the magnitude of side
effects varies with individuals.
DR. MADIA5: In describing your clinical trials using anti-LFA-1
or anti-IL2R mAbs, you emphasized that you avoided the co-
administration of cyelosporine A. Was this done primarily to aid
in the interpretation of the data or to potentially prevent the
possible selection by lymphocytes of an alternative growth path-
way to IL2?
DR. SouLILLou: In first grafts, almost 100% of acute first
rejection episodes that might occur despite mAb treatment would
have been reversed by steroids and ATG, if needed. Therefore,
CsA was not given with the tested reagent because the risk of
over-immunosuppression from CsA appeared to us potentially
more dangerous than that of a rejection episode.
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): Could you comment on the impact of cold isehemia
on expression of ICAM in the endothelial cells of the grafts, and
whether that can have an impact on blockade of LFA? In your
original trial, did you note any relationship of cold ischemia time
to the incidence of rejection?
DR. SouLILLou: We have not studied the effect of ischemia on
ICAM-1 expression. However, in contrast to ICAM-1, LFA-1
expression is not regulated by eytokines. I see no reason why an
increased expression of ICAM-1 molecules will affect the LFA-1
inhibition by the mAb. In fact, the unregulated LFA-1 expression
is probably an advantage of using anti-LFA-1 instead of anti-
ICAM-1.
DR. MADIA5: Regarding the possible relationship between
ICAM-1 and renal isehemia, I should mention the exciting
preliminary data that Dr. Joseph Bonventre of the Massachusetts
General Hospital presented to us recently at a research seminar.
Administration of an anti-ICAM-1 antibody to rats at the time of
ischemia or even 2 hours after the isehemie period resulted in
marked functional and morphologic protection [114].
DR. SouLILLou: Cosimi's group recently reported a preliminary
study in Transplantation suggesting that anti-ICAM-1 prevents
delayed graft function of transplants stored at 4°C for more than
48 hours [61]. However, only few patients with high enough
anti-ICAM-1 trough levels were studied, and these results need
confirmation. If this protective effect is related to the inhibition of
leukocyte adhesion to isehemic endothelial cells by interfering
with the ICAM-1/LFA-1 interaction, then blocking of LFA-1
should be even more effective because more ligands (ICAM-2, -3,
and unknown) should be involved. As in our pilot study with the
anti-CD11a, cold ischemia time longer than 48 hours was an
exclusion criterion, and we have to wait for the result of a
currently running randomized study to assess the effect of the
inhibition of LFA-1/ICAM interactions on delayed graft function.
However, several reports now indicate that administration of
soluble sugars, which are the ligands of selectin involved in the
first step of the interaction of leukoeytes with endothelial cells, is
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effective in decreasing the inflammatory lesions on tissue micro-
vasculature [52]. Similarily, inhibition of IL-8, which also indi-
rectly controls the adhession process, decreases the reperfusion
syndrome [115]. Inhibition of LFA-1/ICAM-1 interaction, which
comes later in this cascade, is probably also effective. I am
personally convinced that the inhibition of adhesion molecules
(integrins, L, E, or P selectins) or their ligands will be important
in the future.
DR. JOHN T. HARRJNGTON (Chief of Medicine, Newton- Wellesley
Hospital, Newton, Massachusetts): I have two questions. First, does
standard ATG have an effect on any of the targets that you
discussed today? Second, can you expand on the term "immuno-
logic correlates"? What specific tests would you use in monitoring
renal transplant recipients? You mentioned the site occupancy of
LFA1. What other tests might be employed?
DR. SOULILLOU: Anti-thymocyte globulin contains antibodies
against a variety of targets [116]. However, I know of no evidence
for attributing its effect to a single specificity. In this respect it is
possible to consider ATG a "cocktail" of various mAbs.
The second part of your question relates to the monitoring of
the effects of such bioreagents. Clearly, one cannot monitor
accurately all the effects of ATG, although some of its effect—for
instance, inhibition of AETTcell rosetting—is of great practical
importance [117]. But monoclonal antibodies usually have the
advantage of allowing monitoring based on specific parameters.
However, the relevance of such monitoring is confirmed only by
the accumulation of clinical correlations. The monitoring can
indicate a state of insufficient immunosuppression that is some-
times related to the host immune response, for instance, against
the murine antibodies. For example, in our pilot study of the
anti-LFA-1 trough levels, inhibition of conjugates between patient
T-cells and DAUDI cells, CD11a and CD18 surface modulation,
and CD1 la site occupancy were compared with each other. The
site occupancy test, technically the simplest, had a good correla-
tion with the others (Le Mauff B, personal communication).
However, only a large clinical experience will ascertain the
relevance of this test.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): I would like your comments on two issues. The first issue
regards chronic rejection. Brenner and coworkers have suggested
that nephron number and hyperfiltration, rather than immuno-
logic factors, are key factors in the pathogenesis of chronic
rejection [118]. Do you agree with this view? Furthermore if, as I
suspect, your view supports an immunologic basis for the syn-
drome, what is the status of research of relevant targets in chronic
rejection?
My second question relates to the immunologic phenomenon
denoted by the term "modulation," that is, endocytosis of cell-
surface markers. Although modulation of CD3 secondary to
OKT3 has been documented [27, 28], it does not appear to be of
clinical significance because T-cells without CD3 are immunolog-
ically ineffective. However, does anti-CD4 therapy cause modula-
tion of the CD4 molecule? Furthermore, could the limited benefit
of anti-CD4 therapy be related to modulation?
DR. SOULILLOU: Dr. Brenner's hypothesis is attractive, although
I think that "in addition to" would be wiser than "rather than,"
because there is a large body of information on the importance of
immune mechanisms in chronic rejection; for instance, fully
matched kidneys have less frequent chronic rejection. The precise
immunologic mechanisms of chronic rejection and their relevant
targets are yet totally unknown. However, decreasing the inci-
dence of early acute rejection by an efficient prophylactic treat-
ment might be a way of decreasing the incidence of chronic
rejection.
Regarding your question on modulation, I do not agree that the
CD3 modulation is not a relevant test because CD3 — cells are
"immunologically ineffective." Indeed, it is that test that tells you
that CD3 has been modulated. It seems to me that a test that
tells us that T-cell function is impaired during OKT3 treatment is
important in many circumstances, particularly when neutralizing
antibodies are suspected. However, better information could
come from analysis of cells infiltrating that graft during anti-CD3
treatment.
Regarding the anti-CD4 effect, some anti-CD4 mAbs cause
modulation, but not all. That the effectiveness of an anti-CD4
correlates with its capacity to modulate anti-CD4 at the lympho-
cyte membrane would appear logical. However, K. Wood, of
Oxford, presented preliminary evidence at the September 1993
Basic Science Symposium in Transplantation that, in the murine
model, the capacity of CD4 modulation of an anti-CD4 mAb
might not be an advantage for induction of tolerance, but rather
that modulation might be a "defense" mechanism in this partic-
ular case, More information is needed.
DR. BHARAT V. Siu (Head, Nephrology Section, P.D. Hinduja
National Hospital and Medical Research Centre, Bombay, India):
Did I hear you correctly that monoclonal antibodies to adhesion
molecules are effective in preventing rejection but not as effective
in treating an acute rejection episode? If that is the case, what is
the explanation?
DR. SouLILLou: Yes, the use of the same mAb, administered in
sufficient amounts, was not able to reverse ongoing rejection in
human recipients [5]. LFA-1 is always expressed on leukocytes. As
LFA-1/ICAM-1 interaction is involved in adhesion between lym-
phocytes and endothelial cells, interfering with this interaction
immediately (or even before grafting) impairs a major step of
allorecognition. During rejection, effector mechanisms are multi-
ple, and interfering with a single function might not be enough. If
confirmed, the effectiveness of anti-LFA-1 given prophylactically,
contrasting with its absence of effect in ongoing rejection, would
suggest that it acts mostly at the level of trafficking of the cells into
the graft. Interestingly, experimentally tolerant mice treated with
a mixture of anti-LFA-1 and anti-ICAM-1 harbor no cellular
infiltrate [15], a pattern opposite to that observed in donor-
specific blood-induced tolerance, for instance [14].
DR. MADJAS: Does the degree of pre-sensitization of the
recipient affect the responsiveness to immune intervention with
the mAbs you described? Is there a difference in the development
of host immunization against these mAbs between clinical re-
sponders versus nonresponders?
DR. SOULILLOU: We observed no correlation between the pres-
ence, or the level, of anti-panel reactive antibodies and the
immune response of the host against the murine antibodies in
the anti-IL2R study in which hyperimmunized patients were
included. However, as hyperimmunized patients were excluded
from the anti-LFA-1 study, I cannot answer your question.
DR. MADIAS: Excluding ICAM-1, are the other adhesion mol-
ecules you mentioned expressed on endothelial cells in the basal
state?
DR. SOULJLLOU: Regulation involves mostly ICAM-1. ICAM-2
is constitutively expressed at a high level on resting endothelial
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cells and is not augmented by activation [119]; in contrast,
ICAM-1 is only weakly expressed on resting endothelial cells.
DR. MADIAs: Do LFA-1(+) or IL2R(+) lymphocytes remain in
the circulation during treatment with the corresponding mAbs?
For how long after discontinuation of therapy do the mAbs
remain in the recipient sera?
DR. S0ULILL0u: Concerning studies with the anti-1L2 receptor,
only about 1% to 2% of circulating cells expressing P55 (a chain
of IL2R) could be found during the treatment [96], However, it is
difficult to ascertain that the mAb was the cause of this because
the concomitant administration of steroids is lymphopenic. Highly
sensitive methods of cytofluorometry performed in recipients of
another anti-P55 mAb does not suggest that the mAb was either
depleting or modulating (Amlot P, personal communication).
Clearly, the situation can change with the mAb.
Regarding the second part of your question, in anti-IL2R
treatment, no circulating mAb was found 1 to 2 days after
cessation of treatment. In patients who had received anti-CD11a,
the circulating mAb was present much longer; in fact, significant
trough levels were observed between days 4 and 10 after the end
of the treatment.
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